At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
NasoVAXbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
In Brief
A Phase 2 clinical trial evaluating NasoVAX for Influenza. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartSep 2017
Primary CompletionMar 2018
Study CompletionJun 2018
TodayJul 2026
First PostedJul 28, 2017
Enrollment StartSep 18, 2017
Primary CompletionMar 7, 2018
Study CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.9 years ago
Interventions
NasoVAXbiological
Single ascending dose study